Open AccessPlasma levels of matrix metalloproteinase‐9 (MMP‐9) are associated with cognitive performance in patients with schizophrenia
Author(s) -
Kudo Noriko,
Yamamori Hidenaga,
Ishima Tamaki,
Nemoto Kiyotaka,
Yasuda Yuka,
Fujimoto Michiko,
Azechi Hirotsugu,
Niitsu Tomihisa,
Numata Shusuke,
Ikeda Manabu,
Iyo Masaomi,
Ohmori Tetsuro,
Fukunaga Masaki,
Watanabe Yoshiyuki,
Hashimoto Kenji,
Hashimoto Ryota
Publication year - 2020
Publication title -
neuropsychopharmacology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.661
H-Index - 13
ISSN - 2574-173X
DOI - 10.1002/npr2.12098
Subject(s) - schizophrenia (object oriented programming) , wechsler adult intelligence scale , psychology , cognition , matrix metalloproteinase 9 , antipsychotic , medicine , pathophysiology , effects of sleep deprivation on cognitive performance , risperidone , positive and negative syndrome scale , psychiatry , clinical psychology , psychosis , matrix metalloproteinase
Aim Matrix metalloproteinase‐9 (MMP‐9) has been shown to modulate synaptic plasticity and may contribute to the pathophysiology of schizophrenia. This study investigated the peripheral levels of MMP‐9 and its association with cognitive functions in patients with schizophrenia to see the possible involvement of MMP‐9 in pathophysiology of schizophrenia, especially in cognitive decline. Methods We measured the plasma levels of MMP‐9 in 257 healthy controls and 249 patients with schizophrenia, including antipsychotic drug–free patients. We also explored the possible association between plasma MMP‐9 levels and cognitive performance in healthy controls and patients with schizophrenia using the Wechsler Adult Intelligence Scale, Third Edition (WAIS‐ III), the Wechsler Memory Scale‐Revised (WMS‐R), and the Rey Auditory Verbal Learning Test (AVLT). Results We found that the plasma levels of MMP‐9 were significantly higher in patients with schizophrenia, including antipsychotic drug–free patients, than in healthy controls. We found a significant negative association between plasma MMP‐9 levels and cognitive performance in controls and patients with schizophrenia. Conclusion Together, these convergent data suggest a possible biological mechanism for schizophrenia, whereby increased MMP‐9 levels are associated with cognitive impairment.